Nirogacestat
Small molecule
Also known as PF-03084014
Evidence outlook
Approved: Desmoid Tumors
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Multiple Myeloma · Phase 1/2 · investigational in the US
Also approved (1)
- Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
DeFi NCT03785964 · Desmoid Tumor, Aggressive Fibromatosis This was a randomized, quadruple-blind, placebo-controlled trial of 142 participants with a hard clinical tumor endpoint, progression-free survival. The primary comparison was statistically significant in favor of nirogacestat: median progression-free survival was not reached with nirogacestat versus 15.1 months with placebo, with HR 0.29 (95% CI 0.15–0.55; p<0.001). Registry: NCT03785964 | 3 | Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. (On the first day of every 3 cycles (each cycle is 28 days) until disease progression is observed or death, whichever comes first, assessed up to approximately 2 years) 2022-04-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Gamma-secretase (presenilin complex) drugs
Varegacestat. Compare all 2 Gamma-secretase (presenilin complex) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Desmoid Tumors: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nirogacestat: this drug | Approved | Small molecule | Gamma-secretase (presenilin complex) | Reliable signal | No reviewed efficacy summary in this indication | |
| Varegacestat | Phase 2/3 | Small molecule | Gamma-secretase (presenilin complex) | Partial signal | NCT04871282: Primary endpoint, progression-free survival vs placebo: HR 0.16 (95% CI 0.071-0.375; p<0.0001); confirmed ORR 56% vs 9% (RINGSIDE, 2025-12-15). |
Compare side by side
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Nirogacestat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.